Discovering novel T cell receptors

We are focused on T cell receptor engineered T cell therapies, TCR-Ts, a promising modality that holds the potential to generate transformational responses in patients with solid tumors. Our unique approach to developing T cell therapies is based on our proprietary MyT platform, a next-generation T cell receptor and epitope discovery engine. We believe there are multiple benefits to leveraging our MyT platform to develop TCR-Ts.

Discover novel, tumor-specific, human TCRs

Generate TCRs of high affinity and specificity

Target a broad array of cancer-related antigens

Our Technology


Advancing portfolio of TCR therapies for solid tumors

Through the use of natural, fully human TCRs, T-knife’s product candidates are designed to induce an organically optimized immune signaling cascade intended to stimulate a potent T cell-driven immune response. Our TCR therapies target tumor-specific antigens in multiple, difficult to treat solid tumor indications.

Our Pipeline

Looking for talented employees who will boldly embrace our mission to bring transformative therapies to people with cancer

Join Our Team